Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furosemide Stress Test for Predicting AKI Progression in ICU Patients
NCT06765031Completed
- Sponsor
- Gulhane Training and Research Hospital
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of furosemide in acute kidney injury (AKI), sponsored by Gulhane Training and Research Hospital. Primary endpoint: Progression from AKI Stage 1-2 to Stage 3 at 14 days. Started Nov 2024; status: completed.
02
Drugs
furosemide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06765031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765031.